Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 18/6/2018
SIETES contiene 92381 citas

 
 
 1 a 20 de 2104 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Pasternak B, Inghammar M, Svanström H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. BMJ 2018;360:8 de marzo. [Ref.ID 102640]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
Tsourdi E, Rachner TD, Hofbauer LC. Romosozumab versus alendronate and fracture risk in women with osteoporosis. N Engl J Med 2018;378:11 de enero. [Ref.ID 102629]
3.Enlace a cita originalTiene citas relacionadas Cita con resumen
Lewis JR, Schousboe JT, Prince RL. Romosozumab versus alendronate and fracture risk in women with osteoporosis. N Engl J Med 2018;378:11 de enero. [Ref.ID 102628]
4.Enlace a cita originalTiene citas relacionadas Cita con resumen
Song GG, Lee YH. Romosozumab versus alendronate and fracture risk in women with osteoporosis. N Engl J Med 2018;378:11 de enero. [Ref.ID 102627]
5. Cita con resumen
Anónimo. Atezolizumab: Myocarditis. Canada. WHO Drug Information 2018;32:19. [Ref.ID 102622]
6.Enlace a cita original Cita con resumen
Gershon AS, Campitelli MA, Hawken S, Victor C, Sproule BA, Kurdyak P, Selby P. Cardiovascular and neuropsychiatric events after varenicline use for smoking cessation. Am J Respir Crit Care Med 2018;197:913-22. [Ref.ID 102579]
7. Cita con resumen
Elia J. Celecoxib gets partial exoneration from FDA panels. Physician's First Watch 2018:5. [Ref.ID 102574]
8.Enlace a cita original Cita con resumen
Patorno E, Goldfine AB, Schneeweiss S, Everett BM, Glynn RJ, Liu J, Kim SC. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. BMJ 2018;360:6 de febrero. [Ref.ID 102541]
9. Cita con resumen
Bally M, Beauchamp M-E, Abrahamowicz M, Nadeau L, Brophy JM. Risk of acute myocardial infarction with real-world NSAIDs depends on dose and timing of exposure. Pharmacoepidemiol Drug Saf 2018;27:69-77. [Ref.ID 102531]
10.Enlace a cita original Cita con resumen
Wang M-T, Liou J-T, Lin CW, Tsai C-L, Wang Y-H, Hsu Y-J, Lai J-H. Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease. A nested case-control study. JAMA Intern Med 2018;178:febrero. [Ref.ID 102529]
12. Cita con resumen
Benefits NL, Pipe A, West R, Hays JT, Tonstad S, McRae T, Lawrence D, St Aubin L, Anthenelli RM. Cardiovascular safety of varenicline, bupropion, and nicotine patch in smokers. A randomized clinical trial. JAMA Intern Med 2018:9 de abril. [Ref.ID 102506]
13. Cita con resumen
White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L, for the CARES Investigators. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 2018;378:29 de marzo. [Ref.ID 102489]
16. Cita con resumen
Poole R, Kennedy OJ, Roderick P, Fallowfield JA, Hayes PC, Parkes J. Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes. BMJ 2017;359:j5024. [Ref.ID 102147]
17. Cita con resumen
Anónimo. FDA to evaluate increased risk of heart -related death and death from all causes with the gout medicine febuxostat (Uloric). FDA U.S. Food and Drug Administration 2017:15 de noviembre. [Ref.ID 102144]
18. Cita con resumen
Khan Q, Ismail M, Haider I, Haq IU, Noor S. QT interval prolongation in hospitalized patients on cardiology wards: a prospective observational study. Eur J Clin Pharmacol 2017;73:1511-8. [Ref.ID 102127]
19. Cita con resumen
Poluzzi E, Diemberger I, de Ridder M, Koci A, Clo M, Oteri A, Pecchioli S, Bezemer I, Schink T, Ulrichsen SP, Boriani G, Sturkenboom MCJ, De Ponti F, Trifirò G. Use of antihistamines and risk of ventricular tachyarrhythmia: a nested case-control study in five European countries from the ARITMO project. Eur J Clin Pharmacol 2017;73:1499-510. [Ref.ID 102126]
20. Cita con resumen
Anónimo. Fingolimod (Gilenya): nuevas contraindicaciones de uso en pacientes con patología cardiaca subyacente y recomendaciones de revisiones dermatológicas. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2017:6 de noviembre. [Ref.ID 102124]
Seleccionar todas
 
 1 a 20 de 2104 siguiente >>